Dr. Clayton Yates - 08 May 2025 Form 4 Insider Report for Genvor Inc

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GNVR on OTC
Reported as of: 08 May 2025
Net transaction value: +$100,000
SEC form: 4
Accepted by SEC: 23 Jun 2025, 19:32:01 UTC
Prior SEC filing: 14 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Dr. Clayton Yates

Key filing fact

Dr. Clayton Yates filed Form 4 for Genvor Inc on 23 Jun 2025.

Key facts

This page summarizes Dr. Clayton Yates's Form 4 filing for Genvor Inc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jun 2025, 19:32.

Change

Previous filing in this sequence was filed on 14 Nov 2023.
Current net transaction value: +$100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002000242 Primary reporting owner

Yates Clayton Clopton

Relationship: Director, 10%+ Owner
Address: 1550 W HORIZON RIDGE PKWY, STE R #3040, HENDERSON
Signature: /s/ Dr. Clayton Yates
Signature date: 23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GNVR transaction

Common Stock

Award

Transaction value: $100,000
Shares: +400,000
Change %
Price: $0.2500
Shares after: 400,000
Date: 08 May 2025
Ownership: ACT Holdings, LLC
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Conversion of $100,000 in accrued payables due to Dr. Yates at $0.25/share. The issuance of the 400K shares to Clayton in consideration of his conversion of $100K in accrued payables, pursuant to Dr. Yates's restructured compensation package, which permits Dr. Yates to convert amounts due to him into common stock.

Footnote F2

Dr. Yates is a manager of, and may therefore be deemed to be the beneficial owner of shares held in the name of, ACT Holdings, LLC.